Labcorp Drug Development
Labcorp Drug Development is the CRO and central laboratory arm of Labcorp (NYSE: LH) that provides nonclinical, central lab, and commercialization services to biopharmaceutical sponsors across more than 100 countries, supported by 14,000+ employees.
- Company typePublic
- Founded1978
- HeadquartersPrinceton, United States
- Headcount5,001–10,000
- GTM typeB2B
- OfferingServices
What Labcorp Drug Development does
Labcorp Drug Development is the contract research and central laboratory arm of Laboratory Corporation of America Holdings (NYSE: LH), focused on supporting biopharmaceutical sponsors across the full drug development lifecycle. The unit, which traces its operational lineage to Covance (now integrated under the Labcorp brand), delivers nonclinical development services (toxicology, pharmacology, metabolism, discovery studies), central laboratory services that generate clinical trial data across more than 100 countries, and post-approval commercialization support including companion diagnostics, sponsored testing, and regulatory consulting. Specialty modality coverage spans cell and gene therapies, antibody-drug conjugates, radiopharmaceuticals, biomarkers, genomics, and precision medicine, with a dedicated Global Trial Connect service launching to coordinate complex global trials.
The technology layer is anchored by integrated digital pathology with AI for diagnostic accuracy, bioanalytical sciences for nonclinical and clinical use, and a global kit-production and specimen-logistics backbone that feeds Labcorp's central lab data advantage. Pricing is quote-based, negotiated per study and per service rather than publicly disclosed, and the go-to-market is enterprise field sales targeting biopharmaceutical sponsors with dedicated biopharma portals and direct engagement. Customer segments are broadly horizontal: biopharmaceutical companies (primary), investigator sites, and patients benefiting from companion diagnostic programs.
The business makes money through multi-phase, multi-year professional services contracts with biopharma sponsors, with revenue streams organized into nonclinical CRO services, central lab services, and commercialization services. Labcorp claims to have supported 76% of all FDA-approved drugs and therapeutic products and 86% of FDA-approved oncology drugs in 2024. The workforce exceeds 14,000 colleagues globally, operating flagship nonclinical labs in Madison (Wisconsin) and Indianapolis (Indiana), European hubs in Harrogate (UK) and Geneva (Switzerland), and Asia-Pacific labs across China, Japan, Singapore, India, and South Korea. Recent corporate actions include acquisitions of a South America CRO in June 2023 and BioReference Health's oncology and clinical testing assets in September 2025.
Labcorp Drug Development firmographics
Firmographics- Name
- Labcorp Drug Development
- Legal name
- Labcorp
- Website
- https://drugdevelopment.labcorp.com
- Company type
- Public
- Founded year
- 1978
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Labcorp Drug Development is the CRO and central laboratory arm of Labcorp (NYSE: LH) that provides nonclinical, central lab, and commercialization services to biopharmaceutical sponsors across more than 100 countries, supported by 14,000+ employees.
- Ownership category
- akta.pro rank
Labcorp Drug Development industry classification
Industry- Product category
- Contract Research Services
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Clinical CROs (Phase I–IV) (HLAGAAAA)
- akta.pro secondary industries
- Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Clinical Research & Trial Central Laboratories (HLAFAMAL), Toxicology & Safety Assessment CROs (GLP) (HLAGAAAC), Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD), Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)
Keywords
Where Labcorp Drug Development is headquartered
LocationHeadquarters
- HQ city
- Princeton
- HQ country
- United States
- HQ region
- North America
Offices10 records
Markets served
Labcorp Drug Development business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- Contract Research Organization Services: Comprehensive CRO services spanning nonclinical development (toxicology, pharmacology, metabolism), central laboratory services, and commercialization support for biopharmaceutical companies
- Central Laboratory Services: Clinical trial laboratory services generating trial data and supporting trials in over 100 countries
- Commercialization Services: Post-approval support including companion diagnostics, sponsored testing, and data applications for marketed therapeutics
Go-to-market motion1 record
Distribution channels2 records
Marketing channels9 records
Labcorp Drug Development product offering
Product offeringCore offering
Labcorp Drug Development provides contract research organization (CRO) and clinical laboratory services to biopharmaceutical companies, spanning nonclinical development (toxicology, pharmacology, metabolism), central laboratory services across 100+ countries (bioanalytical, biomarkers, genomics, companion diagnostics), and commercialization services including regulatory consulting, sponsored testing, and companion diagnostics development. The company supports the full drug development lifecycle from discovery through post-approval commercialization.
Product overview
Labcorp Drug Development (also operating as Covance) provides an integrated platform of biopharma contract research and clinical laboratory services. The offering spans three core pillars: Nonclinical Development (toxicology, pharmacology, metabolism, and discovery studies), Central Lab Services (bioanalysis, biomarkers, genomics, companion diagnostics across 100+ countries), and Commercialization Services (regulatory consulting, sponsored testing, data applications). Supporting capabilities include specialized modalities such as cell and gene therapies, precision medicine, and antibody drug conjugate testing. The portfolio also includes technology enablers like Global Trial Connect for complex trial management. Labcorp's services are delivered through a global network spanning North America (flagship locations in Madison, WI and Indianapolis, IN), Europe (Harrogate, U.K. and Geneva, Switzerland), and Asia-Pacific (China, Japan, Singapore, India, South Korea). The company claims to have supported 76% of all FDA-approved drugs in 2024 and 86% of oncology drug approvals.
Differentiator
Problem solved
Functional benefit
Products and services
- Nonclinical Development Scientific services including toxicology, pharmacology, metabolism, and discovery studies to propel drug development programs across all phases and modalities. For biopharmaceutical companies seeking preclinical drug development support.
- Central Lab Services Industry-leading central laboratories generating clinical trial data across 100+ countries, supporting bioanalytical, biomarkers, genomics, and companion diagnostics for clinical trials.
- Commercialization Services End-to-end support from biomarker-driven trial design through therapeutic approval, including companion diagnostics (CDx), sponsored testing, and regulatory consulting. For biopharma companies commercializing therapeutics.
- Global Trial Connect Clinical trial enablement service designed to support increasingly complex clinical trials with global reach. For biopharmaceutical sponsors managing global clinical trials.
- Cell and Gene Therapy Services Specialized central lab services supporting cell and gene therapy development and clinical trials. For biopharma sponsors developing cell and gene therapies.
- Companion Diagnostics (CDx) Development Development of companion diagnostics to ensure therapeutics reach the right patients upon approval. For biopharma companies seeking co-developed CDx with their therapeutics.
- Antibody Drug Conjugate (ADC) Testing Services Specialized testing services for antibody drug conjugate development supporting preclinical and clinical trials. For biopharma companies developing ADCs.
- Regulatory Consulting Regulatory guidance and consulting services to navigate complex regulatory requirements across global markets. For biopharma companies seeking regulatory strategy support.
Quantifiable outcome
- Labcorp supported 76% of all drugs and therapeutic products approved by the FDA in 2024
- +1 more outcomes
Companies that use Labcorp Drug Development
Customer profileSegments3 records
Ideal customer profiles2 records
Labcorp Drug Development technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Labcorp Drug Development partnerships and signals
Strategic signalScale indicators9 records
Recent moves5 records
Expansion highlights6 records
Labcorp Drug Development competitors and assessment
Company assessmentMarket position
Competitive moat7 records
Key risks5 records
Key highlights6 records
Customer concentration
Labcorp Drug Development social profiles
Digital presenceLabcorp Drug Development financial estimates
Financial estimateRevenue estimate
Valuation estimate
Labcorp Drug Development leadership team
Management profileNumber of profiles
Profiles2 records
Labcorp Drug Development subsidiaries and ownership
Company hierarchySubsidiaries2 records
Labcorp Drug Development funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Labcorp Drug Development M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Labcorp Drug Development
What does Labcorp Drug Development do?
Labcorp Drug Development provides contract research organization (CRO) and clinical laboratory services to biopharmaceutical companies, spanning nonclinical development (toxicology, pharmacology, metabolism), central laboratory services across 100+ countries (bioanalytical, biomarkers, genomics, companion diagnostics), and commercialization services including regulatory consulting, sponsored testing, and companion diagnostics development. The company supports the full drug development lifecycle from discovery through post-approval commercialization.
Is Labcorp Drug Development a public or private company?
Labcorp Drug Development is a public company. It is classified as public and is currently operating.
When was Labcorp Drug Development founded?
Labcorp Drug Development was founded in 1978. It employs 5,001 to 10,000 people.
Where is Labcorp Drug Development based?
Labcorp Drug Development is headquartered in Princeton, United States, in the North America region.
How does Labcorp Drug Development make money?
Three revenue lines are on record. Contract Research Organization Services are the primary driver. The others are central Laboratory Services and commercialization Services.
Does Labcorp Drug Development have an API?
No public API is recorded for Labcorp Drug Development.
What industry is Labcorp Drug Development in?
Labcorp Drug Development's product category is Contract Research Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 621511 and its SIC code is 8071.